Clinical Policy Title: Bronchial thermoplasty for severe asthma
|
|
- Oliver Hamilton
- 5 years ago
- Views:
Transcription
1 Clinical Policy Title: Bronchial thermoplasty for severe asthma Clinical Policy Number: CCP.1058 Effective Date: March 1, 2013 Initial Review Date: October 16, 2013 Most Recent Review Date: October 2, 2018 Next Review Date: October 2019 Policy contains: Asthma. Bronchial thermoplasty. Inhaled corticosteroids. Long acting beta agonists. Related policies: CCP.1083 CCP.1009 Exhaled nitric oxide for the diagnosis of lung disease Pulmonary rehabilitation ABOUT THIS POLICY: Prestige Health Choice has developed clinical policies to assist with making coverage determinations. Prestige Health Choice s clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of medically necessary, and the specific facts of the particular situation are considered by Prestige Health Choice when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Prestige Health Choice s clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Prestige Health Choice s clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Prestige Health Choice will update its clinical policies as necessary. Prestige Health Choice s clinical policies are not guarantees of payment Coverage policy Prestige Health Choice considers the use of bronchial thermoplasty for the treatment of severe or nonsevere asthma to be investigational/experimental and therefore, not medically necessary. Limitations: Coverage determinations are subject to benefit limitations and exclusions as delineated by the state Medicaid authority. The Florida Medicaid website may be accessed at All other uses of bronchial thermoplasty for the treatment of severe or non-severe asthma are not medically necessary. Alternative covered services: 1
2 According to the National Asthma Education and Prevention Program Expert Panel Report, Guidelines for the Diagnosis and Management of Asthma : The first line of treatment for patients with severe persistent asthma is inhaled corticosteroids and long-acting beta agonists. If the patient does not achieve control on medium doses of corticosteroids, higher doses of inhaled corticosteroids and long-acting beta agonists are used, as prescribed by treating provider. There is no clear established alternative to bronchial thermoplasty (National Heart, Lung, and Blood Institute, 2007). Background Asthma is a common chronic airway disorder characterized by periods of reversible airflow obstruction, known as asthma attacks. Airflow is obstructed by inflammation and airway hyper-reactivity (contraction of the small muscles surrounding the airways) in reaction to certain exposures. Exposures include exercise; infection; allergens (e.g., pollen); occupational exposures (e.g., chemicals); and airborne irritants (e.g., environmental tobacco smoke). Symptoms may include wheezing, coughing, shortness of breath, and chest tightness. It is not clear how to prevent asthma from developing and there is no cure. Yet the means to control and prevent exacerbations in persons who have asthma are well established in evidence-based clinical guidelines (National Heart, Lung, and Blood Institute, 2018). Currently, over 26 million Americans have asthma, including 8.3 percent of adults and 8.3 percent of children under age 18. Asthma rates have been rising for all ages, racial groups, and genders since the 1980s. Nearly half (11.5 million) of Americans with asthma reported having at least one asthma attack in Asthma accounts for 14.2 million doctor s office visits, 439,000 hospital discharges, and 1.8 million emergency department visits (Asthma and Allergy Foundation of America, 2018). Current guidelines emphasize that asthma therapy be selected on the basis of disease severity. For intermittent asthma, no daily medication is advised for the majority of patients. To relieve occasional symptoms, a rapid-acting, inhaled β2-agonist is prescribed. Patients with mild, persistent asthma require controller medication with a daily inhaled glucocorticoid, to achieve and maintain asthma control. Other treatment options include sustained-release theophylline, chromones, or a leukotriene modifier. For moderate persistent asthma, the preferred therapy is a combination of an inhaled glucocorticoid and a long-acting, inhaled β2-agonist. Sustained-release theophylline or a leukotriene modifier can be used instead of the β2-agonist. Primary therapy for severe, persistent asthma includes an inhaled glucocorticoid at higher doses, in addition to a long-acting, inhaled β2-agonist. Some patients with severe asthma do not achieve acceptable control despite maximal medical therapy (National Heart, Lung, and Blood Institute, 2018). 2
3 Bronchial thermoplasty is intended for the treatment of severe, persistent asthma not well controlled by long-acting bronchodilators or glucocorticoids, in patients 18 years and older. The treatment is designed to weaken and partially destroy the smooth muscle that constricts the airways during asthma attacks. The procedure relies on a catheter that has an expandable array of electrodes and a fiber optic camera, which allows the physician to see inside the lung. After the catheter is threaded into the airway, a wire leading out of the back end of the catheter is attached to a radiofrequency generator, and a lever is operated that causes the electrodes to curl into a ball shape around the front end of the catheter. The curved electrodes are held against the bronchial walls and an electrical current is applied to generate heat that destroys the smooth muscle underneath the lining of the bronchial passages (Mayse, 2007). The complete thermoplasty procedure is performed in three treatment sessions targeting different segments of the lung, with a recovery period of 3 weeks between each session. Bronchial thermoplasty is typically performed by a pulmonologist, with the patient under moderate sedation or general anesthesia. The use of bronchial thermoplasty was evaluated in three randomized controlled trials supported by the manufacturer of the Alair Bronchial Thermoplasty System (Boston Scientific Corporation, 2018). The device was approved by the U.S. Food and Drug Administration in April Searches Prestige Health Choice searched PubMed and the databases of: UK National Health Services Centre for Reviews and Dissemination. Agency for Healthcare Research and Quality s National Guideline Clearinghouse and other evidence-based practice centers. The Centers for Medicare & Medicaid Services. We conducted searches on August 8, Search terms were asthma and bronchial thermoplasty. We included: Systematic reviews, which pool results from multiple studies to achieve larger sample sizes and greater precision of effect estimation than in smaller primary studies. Systematic reviews use predetermined transparent methods to minimize bias, effectively treating the review as a scientific endeavor, and are thus rated highest in evidence-grading hierarchies. Guidelines based on systematic reviews. Economic analyses, such as cost-effectiveness, and benefit or utility studies (but not simple cost studies), reporting both costs and outcomes sometimes referred to as efficiency studies which also rank near the top of evidence hierarchies. Findings 3
4 A number of guidelines from professional societies support the use of bronchial thermoplasty as an addon treatment for selected patients with severe asthma (Global Initiative for Asthma, 2017; Health Improvement Scotland, 2016; American College of Allergy, Asthma, and Immunology, 2015; American College of Chest Physicians, 2014; INTERASMA, 2014). However, some of these sources caution that the evidence supporting use of this treatment is limited, and that clinicians should carefully advise patients of potential risks and benefits before therapy begins. A review by the Agency for Healthcare Quality and Research evaluated 15 studies (n = 432), three of which were randomized controlled trials, for persons with severe asthma. Outcomes after bronchial thermoplasty plus standard care (continued medical management) versus sham bronchial thermoplasty plus standard care were compared. Asthma control, hospitalizations for respiratory symptoms, use of rescue medications, pulmonary physiology measures, or quality of life scores were not significantly different between the two groups. bronchial thermoplasty, compared with sham thermoplasty or standard care was linked with fewer severe exacerbations and emergency visits, but also with higher rates of hospitalization (D Anci, 2017). A Cochrane review of three randomized controlled trials of 249 patients with severe persistent asthma compared bronchial thermoplasty with medical management or a sham intervention (Torrego, 2014). Results affirmed those in a meta-analysis three years prior (Wu, 2011), and showed that bronchial thermoplasty, in comparison with other groups: Improved quality of life at 12 months, a finding not clinically significant Had the same level of symptoms control Showed a lower rate of exacerbation and emergency department visits (8.4 versus 15.3 percent) after 12 months Documented no significant improvement in pulmonary function parameters (with the exception of a greater increase in morning peak expiratory flow in one trial) Had a significantly greater hospitalization risk for respiratory adverse events during treatment (risk ratio 3.50,representing an increase from 2 to 8 percent over the treatment period Was associated with a rise in respiratory adverse events, mainly during the treatment period. Of the bronchial thermoplasty subjects in the meta-analysis, 216 were followed for five years after treatment. The frequency of respiratory adverse events were significantly reduced (P <.00001). The number of emergency visits and hospitalizations for adverse events were (non-significantly) changed at P =.71 and P =.32 (Zhou, 2016). A systematic review of three trials evaluated the efficacy of bronchial thermoplasty with omalizumab (Xolair), a monoclonal antibody to treat asthma, both compared with sham treatments or placebo. bronchial thermoplasty patients experienced fewer severe exacerbations (P =.62) and hospitalizations (P =.53) butsignificantly fewer emergency department visits (P =.04). Scores on the asthma quality-of-life questionnaire were insignificantly higher for the bronchial thermoplasty group (P =.059). The rate of exacerbations for bronchial thermoplasty was significantly higher at P <.009 (Niven, 2018). 4
5 The randomized controlled trials that made up the above systematic reviews and meta-analyses include a small trial from the United Kingdom, known as the Research in Severe Asthma trial. A five-year followup of 14 asthma patients taking bronchial thermoplasty along with corticosteroids and β2 agonists compared outcomes for year 1 to year 2 5 after bronchial thermoplasty treatment. No changes were observed for adverse events or in lung function, and declines in hospitalizations and emergency visits for respiratory symptoms were observed (Pavord, 2013). These five-year findings matched those from the first year post-treatment (Pavord, 2007). A second, and also small, trial of bronchial thermoplasty is known as the Asthma Information Research trial. A randomized controlled trial of 45 patients treated with bronchial thermoplasty and 24 control patients not given bronchial thermoplasty reviewed five-year outcomes. Respiratory adverse events per subject for the five years after bronchial thermoplasty treatment were 4.5, 1.2, 1.3, 1.2, and 1.1, not different than the 3.1, 1.2, and 1.3 figures for controls (which were not followed in years 4-5). There was no elevated rate in hospital or emergency room visits for respiratory symptoms in years 2-5 for the bronchial thermoplasty group (Thomson, 2011). The trial confirmed results for the 12 month posttreatment period (Cox, 2007). The third, and largest of the three randomized controlled trials is known as AIR2. It first compared 190 subjects in the bronchial thermoplasty group and 98 in the sham group one year after treatment. bronchial thermoplasty consistently showed superior efficacy in net benefit in Asthma Quality of Life Questionnaire score (76 versus 57 percent), percent with severe exacerbations (26.3 versus 39.8), days per year lost from work and school (1.32 versus 3.92), percent of subjects with adverse respiratory events reported (70 versus 80), and emergency visits per subject per year for respiratory symptoms (0.07 versus 0.43) (Castro, 2010). Similar results were observed after the second year post-treatment (Castro, 2011). A more recent report updated AIR2 results, and compared results in the year prior to treatment with the five years after treatment. A 48 percent reduction in exacerbation and 88 percent reduction in emergency visits in the bronchial thermoplasty group were both significant. No changes were observed in pre- bronchial thermoplasty, Forced Expiratory Volume or respiratory-related adverse events, and hospitalizations (Weichsler, 2013). Policy updates: A total of five clinical guidelines/other and one peer reviewed reference were added to, and four clinical guidelines/other were removed from this policy in August Summary of clinical evidence: Citation D Anci (2017) Content, Methods, Recommendations Key points: 5
6 Citation Effectiveness and safety of bronchial thermoplasty Zhou (2016) Content, Methods, Recommendations A review by the Agency for Healthcare Quality and Research of 15 studies (n = 432). All patients had severe asthma, three of were randomized controlled trials. Bronchial thermoplasty and standard care compared to standard care (continued medical management) alone improved Asthma Quality of Life Questionnaire scores significantly, but this had no clinical importance. Studies that compared outcomes after bronchial thermoplasty plus standard care (continued versus sham bronchial thermoplasty plus standard care found asthma control, hospitalizations for respiratory symptoms, use of rescue medications, pulmonary physiology measures, or quality of life scores were no different between the two groups. Studies also found that bronchial thermoplasty was linked with fewer severe exacerbations and emergency visits. Studies found higher rates of hospitalization (significant) in the bronchial thermoplasty group, along with insignificantly higher rates of upper respiratory tract infections, wheezing, dyspnea, lower respiratory tract infections, anxiety, and segmental atelectasis, Key points: Summary of bronchial thermoplasty trials five years after treatment Meta-analysis of 216 persons with severe asthma given bronchial thermoplasty versus standard medical management or sham treatment, followed five years after treatment. Bronchial thermoplasty was associated with reduced frequency of respiratory adverse events were (rate ratio (RR) 3.41, P <.00001). The number of emergency visits and hospitalizations for adverse events were unchanged at RR =1.06 (P =.71) and RR =1.47 (P =.32). Torrego (2014) Key points: Summary of bronchial thermoplasty trials one year after treatment Cochrane review of 249 persons with severe asthma given BT versus standard medical management or sham treatment, followed one year after treatment. Bronchial thermoplasty improved quality of life at 12 months, a finding not clinically significant. Both groups had the same level of symptoms control. Bronchial thermoplasty patients showed a lower rate of exacerbation and emergency department visits (8.4 versus 15.3 percent (%)) after 12 months. No significant improvement in pulmonary function parameters were observed for bronchial thermoplasty patients (except for a greater increase in morning peak expiratory flow in one trial). Bronchial thermoplasty had a significantly greater hospitalization risk for respiratory adverse events during treatment (risk ratio 3.50, an increase from 2 to 8%). Bronchial thermoplasty was associated with a rise in respiratory adverse events, mainly during the treatment period. Wechsler (2013) Key points: Large trial of bronchial thermoplasty five years after treatment Randomized controlled trial updating 2010 study, comparing bronchial thermoplasty versus sham treatment efficacy five years after treatment. A 48% reduction in exacerbation and 88 percent reduction in emergency visits in the BT group were both significant. No changes were observed in pre-bronchial thermoplasty Forced Expiratory Volume or respiratory-related adverse events, and hospitalizations. 6
7 Citation Castro (2010) Content, Methods, Recommendations Key points: Large trial of bronchial thermoplasty one year after treatment Randomized controlled trial of 190 subjects given bronchial thermoplasty and 98 given sham treatment. One year after treatment, patients in the bronchial thermoplasty group consistently showed superior efficacy in net benefit in Asthma Quality of Life Questionnaire score (76 versus 57 percent), percent with severe exacerbations (26.3 versus 39.8), days per year lost from work and school (1.32 versus 3.92), percent of subjects with adverse respiratory events reported (70 versus 80), and emergency visits per subject per year for respiratory symptoms (0.07 versus 0.43). References Professional society guidelines/other: Akinbami LJ, Moorman JE, Bailey C, et al. Trends in Asthma Prevalence, Health Care Use, and Mortality in the United States, Atlanta GA: U.S. Centers for Disease Control and Prevention, National Center for Health Statistics. National Center for Health Statistics Data Brief No. 94, May Accessed August 7, American College of Allergy, Asthma and Immunology Statement on bronchial thermoplasty. Arlington Heights IL: American College of Allergy, Asthma, and Immunology, January 1, Accessed August 7, American College of Chest Physicians. Position statement for coverage and payment for bronchial thermoplasty. American College of Chest Physicians, May 12, Accessed August 7, American Lung Association. Trends in Asthma Morbidity and Mortality. Washington DC: American Lung Association, September Accessed August 7, Asthma and Allergy Foundation of America. Asthma Facts and Figures. Landover MD: Asthma and Allergy Foundation of America, Accessed August 8, Boston Scientific Corporation. The Alair Bronchial Thermoplasty System. Natick MA: Boston Scientific Corporation, March Accessed August 8,
8 D Anci KE, Lynch MP, Leas BF, et al (eds.). Effectiveness and Safety of Bronchial Thermoplasty in Management of Asthma [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); Report No.: 18-EHC003-EF. Global Initiative for Asthma GINA Report: Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma, Accessed August 7, Healthcare Improvement Scotland. SIGN 153: British guidelines on the management of asthma: a national clinical guideline. Edinburgh: Healthcare Improvement Scotland, September Accessed August 8, INTERASMA, the Global Asthma Association. Bronchial thermoplasty: an additional option for managing patients with severe asthma. INTERASMA, Accessed August 8, National Heart, Lung, and Blood Institute, National Institutes of Health. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. National Institutes of Health Publication No Bethesda MD: National Heart, Lung, and Blood Institute, Accessed August 8, National Heart, Lung, and Blood Institute, National Institutes of Health. Asthma. Bethesda MD: National Heart, Lung, and Blood Institute, Accessed August 8, National Institute for Health and Clinical Excellence. Bronchial Thermoplasty for severe asthma London: National Institute for Health and Clinical Excellence, NICE Interventional Procedure Guidance No Accessed August 8, Peer-reviewed references: Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008; 31(1): Doi: / Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of Bronchial Thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010;181(2): Doi: /rccm OC. Castro M, Rubin A, Laviolette M, et al.; AIR2 Trial Study Group. Persistence of effectiveness Bronchial Thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011;107(1): Doi: /j.anai
9 Cox G, Thomson NC, Rubin AS, et al.; AIR Trial Study Group. Asthma control during the year after Bronchial thermoplasty. N Engl J Med. 2007;356(13): Cox G. Bronchial thermoplasty for severe asthma. Curr Opin Pulm Med. 2011;17(1): Doi: /MCP.0b013e ae4. Mayse ML, Laviolette M, Rubin A, et al. Clinical pearls for bronchial thermoplasty. J Bronch. 2007;14(2): Doi: /LBR.0b013e318054dbed. Niven RM, Simmonds MR, Cangelosi MJ, Tilden DP, Cottrell S, Shargill NS. Indirect comparison of bronchial thermoplasty versus omalizumab for uncontrolled severe asthma. J Asthma. 2018;55(4): Doi: / Pavord ID, Cox G, Thomson NC, et al. Safety and efficacy of Bronchial Thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007;176(12): Pavord ID, Thomson NC, Niven RM, et al. Safety of bronchial thermoplasty in patients with severe refractory asthma. Ann Allergy Asthma Immunol. 2013;111(5): Doi: /j.anai Thomson NC, Rubin AS, Niven RM, et al. Long-term (5 year) safety of bronchial thermoplasty: Asthma Intervention Research (AIR) trial. BMC Pulm Med. 2011;11:8. Doi: / Torrego A, Sola I, Munoz AM, et al. bronchial thermoplasty for moderate or severe persistent asthma in adults. Cochrane Database Syst Rev. 2014;(3):CD Doi: / CD pub2. Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013;132(6): Doi: /j.jaci Wu Q, Xing Y, Zhou X, Wang D. Meta-analysis of the efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma. J Int Med Res. 2011;39(1): Zhou JP, Feng Y, Wang Q, Zhou LN, Wan JY, Li QY. Long-term efficacy and safety of bronchial thermoplasty in patients with moderate-to-severe persistent asthma: a systemic review and metaanalysis. J Asthma. 2016;53(1): Centers for Medicare & Medicaid Services National Coverage Determinations: No National Coverage Determinations identified as of the writing of this policy. Local Coverage Determinations: 9
10 No Local Coverage Determinations identified as of the writing of this policy. Commonly submitted codes Below are the most commonly submitted codes for the service(s)/item(s) subject to this policy. This is not an exhaustive list of codes. Providers are expected to consult the appropriate coding manuals and bill accordingly. CPT Code Description Comments Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial Thermoplasty, one lobe. Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, two or more lobes. ICD-10 Code Description Comment J44.0 Chronic obstructive pulmonary disease with acute lower respiratory Infection J44.1 Chronic obstructive pulmonary disease with (acute) exacerbation J44.9 Chronic obstructive pulmonary disease, unspecified J45.20 Mild intermittent asthma, uncomplicated J45.21 Mild intermittent asthma with (acute) exacerbation J45.22 Mild intermittent asthma with status asthmaticus J45.30 Mild persistent asthma, uncomplicated J45.31 Mild persistent asthma with (acute) exacerbation J45.32 Mild persistent asthma with status asthmaticus J45.40 Moderate persistent asthma, uncomplicated J45.41 Moderate persistent asthma with (acute) exacerbation J45.42 Moderate persistent asthma with status asthmaticus J45.50 Severe persistent asthma, uncomplicated J45.51 Severe persistent asthma with (acute) exacerbation J45.52 Severe persistent asthma with status asthmaticus J Unspecified asthma with (acute) exacerbation J Unspecified asthma with status asthmaticus J Unspecified asthma, uncomplicated J Exercise induced bronchospasm J Cough variant asthma J Other asthma HCPCS Level II Code N/A Description Comments 10
Clinical Policy Title: Bronchial thermoplasty for severe asthma
Clinical Policy Title: Bronchial thermoplasty for severe asthma Clinical Policy Number: 07.03.01 Effective Date: March 1, 2013 Initial Review Date: October 16, 2013 Most Recent Review Date: October 19,
More informationHCT Medical Policy. Bronchial Thermoplasty. Policy # HCT113 Current Effective Date: 05/24/2016. Policy Statement. Overview
HCT Medical Policy Bronchial Thermoplasty Policy # HCT113 Current Effective Date: 05/24/2016 Medical Policies are developed by HealthyCT to assist in administering plan benefits and constitute neither
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bronchial_thermoplasty 10/2010 3/2018 3/2019 3/2018 Description of Procedure or Service Bronchial thermoplasty
More informationSubject: Bronchial Thermoplasty
Subject: Bronchial Thermoplasty Guidance Number: MCG-171 Revision Date(s): Original Effective Date: 6/12/14 Medical Coverage Guidance Approval Date: 6/12/14 PREFACE This Medical Guidance is intended to
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Community Plan Medical Policy Policy Number: CS014.E Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2014 Origination: 11/2010 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Oxford Clinical Policy Policy Number: RESPIRATORY 009.11 T2 Effective Date: August 1, 2017 Table of Contents Page BRONCHIAL THERMOPLASTY... 1 INSTRUCTIONS FOR USE...
More informationBRONCHIAL THERMOPLASTY
Review Article 155 BRONCHIAL THERMOPLASTY Prince James* and Richa Gupta* (Received on 4.5.2010; Accepted after revision on 5.9.2011) Summary: Even with the use of maximum pharmacological treatment, asthma
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare of California (HMO) UnitedHealthcare Benefits Plan of California (IEX EPO, IEX PPO) UnitedHealthcare of Oklahoma, Inc. UnitedHealthcare of Oregon, Inc. UnitedHealthcare
More informationBronchial Thermoplasty
Medical Policy Manual Surgery, Policy No. 178 Bronchial Thermoplasty Next Review: September 2018 Last Review: October 2017 Effective: November 1, 2017 IMPORTANT REMINDER Medical Policies are developed
More informationBronchial Thermoplasty For Severe Persistent Asthma
Bronchial Thermoplasty For Severe Persistent Asthma Faisal Khan MD Center For Respiratory and Sleep Medicine Indiana Internal Medicine Consultants Franciscan Saint Francis hospital Agenda Burden of Severe
More informationMedical Review Criteria Bronchial Thermoplasty
Medical Review Criteria Bronchial Thermoplasty Subject: Bronchial Thermoplasty Background: Bronchial thermoplasty is proposed as a treatment option for adults whose severe persistent asthma is not well
More informationBRONCHIAL THERMOPLASTY
BRONCHIAL THERMOPLASTY UnitedHealthcare Commercial Medical Policy Policy Number: 2018T0542L Effective Date: July 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS... 1 COVERAGE
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 4/2018 Origination: 11/2010 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationClinical Policy Title: Strep testing
Clinical Policy Title: Strep testing Clinical Policy Number: 07.01.09 Effective Date: December 1, 2017 Initial Review Date: October 19, 2017 Most Recent Review Date: November 16, 2017 Next Review Date:
More informationRobert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network
Robert Kruklitis, MD, PhD Chief, Pulmonary Medicine Lehigh Valley Health Network Robert.kruklitis@lvh.com Correlation of a Asthma pathophyisology with basic science Asthma (Physiology) Bronchodilators
More informationClinical Policy Title: Cardiac rehabilitation
Clinical Policy Title: Cardiac rehabilitation Clinical Policy Number: 04.02.02 Effective Date: September 1, 2013 Initial Review Date: February 19, 2013 Most Recent Review Date: February 6, 2018 Next Review
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Asthma Education Day Thursday, October 30, 2014 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry Ford Hospital
More informationEndobronchial Thermoplasty
Endobronchial Thermoplasty Michigan Society for Respiratory Care Monday, October 5, 2015 Cynthia Ray, MD, FCCP Senior Staff Physician Interventional Pulmonology Pulmonary and Critical Care Medicine Henry
More informationClinical Policy Title: Zoster (shingles) vaccine
Clinical Policy Title: Zoster (shingles) vaccine Clinical Policy Number: 18.02.10 Effective Date: June 1, 2018 Initial Review Date: April 10, 2018 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationWest of Scotland Difficult Asthma Group Statement of Practice
West of Scotland Difficult Asthma Group Statement of Practice Member Health Boards: Ayrshire and Arran Dumfries and Galloway Forth Valley Lanarkshire Glasgow INFORMATION ON THE USE OF BRONCHIAL THERMOPLASTY
More informationClinical Policy Title: Genicular nerve block
Clinical Policy Title: Genicular nerve block Clinical Policy Number: 14.01.10 Effective Date: October 1, 2017 Initial Review Date: September 21, 2017 Most Recent Review Date: October 19, 2017 Next Review
More informationComplements asthma therapy NOT a CURE for Severe. Non pharmacologic treatment of asthma. limits the ability of the airways to constrict.
Bronchial Thermoplasty Karla Provost Pulmonary and Critical Care Medicine 2015 What is Bronchial Thermoplasty Non pharmacologic treatment of asthma Outpatient procedure performed over 3 treatment sessions
More informationWhat is Severe Persistent Asthma? What is Bronchial Thermoplasty Non pharmacologic treatment of asthma
Objectives BT defined What is Severe Persistent Asthma Case Study introduction How is BT performed Pre-op, PACU and Discharge care Who does it work for the criteria for BT Brief overview of BT results
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: xolair_omalizumab 9/2003 11/2017 11/2018 11/2017 Description of Procedure or Service Asthma is a chronic
More informationSmooth Muscle & Asthma: Bronchial Thermoplasty - A Smooth Muscle Modifier
Smooth Muscle & Asthma: Bronchial Thermoplasty - A Smooth Muscle Modifier Mario Castro, MD, MPH Professor of Medicine and Pediatrics Director, The Asthma and Airway Translational Research Unit, Washington
More informationBronchial Thermoplasty
Bronchial Thermoplasty Policy Number: 7.01.127 Last Review: 9/2018 Origination: 11/2010 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for bronchial
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationRunning Head: THE PRACTICALITY OF BRONCHIAL THERMOPLASTY 1. Review of a New Treatment for Severe Asthma: The Practicality of Bronchial Thermoplasty
Running Head: THE PRACTICALITY OF BRONCHIAL THERMOPLASTY 1 Review of a New Treatment for Severe Asthma: The Practicality of Bronchial Thermoplasty Jessica Orpen Northeastern University THE PRACTICALITY
More informationClinical Policy: Fractional Exhaled Nitric Oxide Reference Number: CP.MP.103
Clinical Policy: Reference Number: CP.MP.103 Effective Date: 01/16 Last Review Date: 01/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory and
More informationLCD for Omalizumab (Xolair ) (L29240)
LCD for Omalizumab (Xolair ) (L29240) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29240 LCD Information
More informationClinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening
Clinical Policy Title: Fluorescence in situ hybridization for cervical cancer screening Clinical Policy Number: 01.01.02 Effective Date: April 1, 2015 Initial Review Date: January 21, 2015 Most Recent
More informationClinical Policy Title: Ketamine for treatment-resistant depression
Clinical Policy Title: Ketamine for treatment-resistant depression Clinical Policy Number: 00.02.13 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent Review Date: January
More informationThe New Medtech Economic Reality MassMEDIC Annual Meeting
The New Medtech Economic Reality MassMEDIC Annual Meeting Susan Posner Vice President sposner@healthadvances.com May 1, 2012 The New Medtech Reality The economic downturn coupled with the focus on health
More information2017 Blue Cross and Blue Shield of Louisiana
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationUsefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function
doi: 10.2169/internalmedicine.8965-17 http://internmed.jp CASE REPORT Usefulness of Bronchial Thermoplasty for Patients with a Deteriorating Lung Function Daisuke Minami, Chihiro Ando, Takamasa Nakasuka,
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationDiagnosis, Treatment and Management of Asthma
Diagnosis, Treatment and Management of Asthma Asthma is a complex disorder characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and an underlying inflammation.
More informationand will be denied as not medically necessary** if not met. This criterion only applies to the initial
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: July 20, 2017 Next
More informationDATE: 09 December 2009 CONTEXT AND POLICY ISSUES:
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 09 December 2009 CONTEXT AND POLICY
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationCase-Compare Impact Report
Case-Compare Impact Report October 8, 20 For CME Activity: Developed through an independent educational grant from Genentech: Moderate to Severe Persistent Asthma: A Case-Based Panel Discussion (March
More informationClinical Policy Title: Abdominal aortic aneurysm screening
Clinical Policy Title: Abdominal aortic aneurysm screening Clinical Policy Number: 08.01.10 Effective Date: August 1, 2017 Initial Review Date: June 22, 2017 Most Recent Review Date: June 5, 2018 Next
More informationClinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden
Clinical Policy Title: Genetic testing for G1691A polymorphism factor V Leiden Clinical Policy Number: 05.01.03 Effective Date: January 1, 2016 Initial Review Date: July 15, 2015 Most Recent Review Date:
More informationAsthma Management for the Athlete
Asthma Management for the Athlete Khanh Lai, MD Assistant Professor Division of Pediatric Pulmonary and Sleep Medicine University of Utah School of Medicine 2 nd Annual Sports Medicine Symposium: The Pediatric
More informationBiologic Agents in the treatment of Severe Asthma
Biologic Agents in the treatment of Severe Asthma Daniel L Maxwell, D.O., FACOI, FAASM Clinical Assistant Professor of Medicine Michigan State University College of Osteopathic Medicine College of Human
More information10801 Sixth St, Rancho Cucamonga, CA Tel (909) Fax (909) Visit our web site at:
for the Diagnosis and Management of Asthma and Other Pulmonary Disorders IEHP Policy: Based on a review of the currently available literature, there is insufficient evidence to support the use of FE NO
More informationSupplementary Medications during asthma attack. Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus
Supplementary Medications during asthma attack Prof. Dr Finn Rasmussen PhD. DrMedSc. Near East University Hospital North Cyprus Conflicts of Interest None Definition of Asthma Airway narrowing that is
More informationNG80. Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Asthma: diagnosis, monitoring and chronic asthma management (NG80) NG80 NICE has checked the use of its content in this product and the sponsor has had no influence on the content of this booklet. NICE
More informationClinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering)
Clinical Policy Title: Altered auditory feedback devices for speech dysfluency (stuttering) Clinical Policy Number: 17.02.02 Effective Date: January 1, 2016 Initial Review Date: August 19, 2015 Most Recent
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Xolair (omalizumab) Page 1 of 15 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Xolair (omalizumab) Prime Therapeutics will review Prior Authorization requests.
More informationClinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab
Clinical Policy Title: Measurement of serum antibodies to infliximab and adalimumab Clinical Policy Number: 01.01.03 Effective Date: January 1, 2016 Initial Review Date: September 16, 2015 Most Recent
More informationPharmacy Medical Policy IgE Receptor Binding Inhibitors
Pharmacy Medical Policy IgE Receptor Binding Inhibitors Table of Contents Policy: Commercial Policy History Endnotes Policy: Medicare Information Pertaining to All Policies Forms Coding Information References
More informationEndobronchial thermoplasty for asthma
Review Article on Aerodigestive Endoscopy Endobronchial thermoplasty for asthma Felix Zamora 1, Roy Cho 1, Madhuri Rao 2, Heidi Gibson 3, H. Erhan Dincer 1 1 Division of Pulmonary, Allergy, Critical Care
More informationClinical Policy Title: Room humidifiers
Clinical Policy Title: Room humidifiers Clinical Policy Number: 17.02.05 Effective Date: February 1, 2017 Initial Review Date: November 16, 2016 Most Recent Review Date: November 16, 2016 Next Review Date:
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationAir Flow Limitation. In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation.
Asthma Air Flow Limitation In most serious respiratory disease, a key feature causing morbidity and functional disruption is air flow imitation. True whether reversible, asthma and exercise-induced bronchospasm,
More informationDISCLOSURE. Dr. Plummer has declared no conflicts of interest related to the content of his presentation.
DISCLOSURE Dr. Plummer has declared no conflicts of interest related to the content of his presentation. New Codes for 2013 NAMDRC Annual Meeting March 23, 2013 Alan L. Plummer, MD Professor of Medicine
More informationThe Acute & Maintenance Treatment of Asthma via Aerosolized Medications
The Acute & Maintenance Treatment of Asthma via Aerosolized Medications Douglas S. Gardenhire, EdD, RRT-NPS, FAARC Associate Professor and Chairman Department of Respiratory Therapy Objectives Define Asthma.
More informationSCREENING AND PREVENTION
These protocols are designed to implement standard guidelines, based on the best evidence, that provide a consistent clinical experience for AHC II Integrated Clinical Delivery Network patients and allow
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Bronchial Thermoplasty Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 7 References... 8 Effective Date... 7/15/2014 Next
More informationDR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL
DR REBECCA THOMAS CONSULTANT RESPIRATORY PHYSICIAN YORK DISTRICT HOSPITAL Definition Guidelines contact complicated definitions Central to this is Presence of symptoms Variable airflow obstruction Diagnosis
More informationXolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit)
Line of Business: All Lines of Business Effective Date: August 16, 2017 Xolair (Omalizumab) Drug Prior Authorization Protocol (Medical Benefit & Part B Benefit) This policy has been developed through review
More informationImproving Outcomes in the Management & Treatment of Asthma. April 21, Spring Managed Care Forum
Improving Outcomes in the Management & Treatment of Asthma April 21, 2016 2016 Spring Managed Care Forum David M. Mannino, M.D. Professor Department of Preventive Medicine and Environmental Health University
More informationHealthPartners Care Coordination Clinical Care Planning and Resource Guide ASTHMA
The following evidence based guideline was used in developing this clinical care guide: National Institute of Health (NIH National Heart, Lung, and Blood Institute (NHLBI) and American Academy of Allergy,
More informationClinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease
Clinical Policy Title: Exhaled nitric oxide for diagnosis of lung disease Clinical Policy Number: 07.01.04 Effective Date: June 1, 2014 Initial Review Date: February 19, 2014 Most Recent Review Date: November
More informationBronchial Thermoplasty for the Treatment of Severe Asthma
TITLE: Bronchial Thermoplasty for the Treatment of Severe Asthma AUTHOR: Jeffrey A. Tice, MD Assistant Professor of Medicine Division of General Internal Medicine Department of Medicine University of California
More informationAsthma Coding Fact Sheet for Primary Care Pediatricians
01/01/2017 Asthma Coding Fact Sheet for Primary Care Pediatricians Physician Evaluation & Management Services Outpatient 99201 99202 99203 99204 99205 Office or other outpatient visit, new patient; self
More informationConnecting Health & Housing: Asthma and the Home. Presented by: The California-Nevada Public Health Training Center
Connecting Health & Housing: Asthma and the Home Presented by: The California-Nevada Public Health Training Center Funded by Grant #UB6HP20202 from the Health Resources and Services Administration, U.S.
More informationClinical Policy Title: Vacuum assisted closure in surgical wounds
Clinical Policy Title: Vacuum assisted closure in surgical wounds Clinical Policy Number: 17.03.00 Effective Date: September 1, 2015 Initial Review Date: June 16, 2013 Most Recent Review Date: August 17,
More informationDiagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016
Diagnosis and Management of Asthma in Children based on the British Thoracic Society and Scottish Intercollegiate Guidelines Network September 2016 Diagnosis: There is no lower limit to the age at which
More information(Asthma) Diagnosis, monitoring and chronic asthma management
Dubai Standards of Care 2018 (Asthma) Diagnosis, monitoring and chronic asthma management Preface Asthma is one of the most common problem dealt with in daily practice. In Dubai, the management of chronic
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: exhaled_nitric_oxide_measurement 2/2009 3/2018 3/2019 3/2018 Description of Procedure or Service Asthma is
More informationMANAGING ASTHMA. Nancy Davis, RRT, AE-C
MANAGING ASTHMA Nancy Davis, RRT, AE-C What is asthma? Asthma is a chronic respiratory disease characterized by episodes or attacks of inflammation and narrowing of small airways in response to asthma
More informationAsthma: diagnosis and monitoring
Asthma: diagnosis and monitoring NICE guideline: short version Draft for second consultation, July 01 This guideline covers assessing, diagnosing and monitoring suspected or confirmed asthma in adults,
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 11.03.05 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: September 21, 2017 Next
More informationClinical Policy Title: Computerized gait analysis
Clinical Policy Title: Computerized gait analysis Clinical Policy Number: 15.01.01 Effective Date: October 1, 2014 Initial Review Date: May 21, 2014 Most Recent Review Date: May 1, 2018 Next Review Date:
More informationASTHMA What Keeps the Wheeze Away. Dr. Janice Bacon MPHCA Annual Conference June 2016
ASTHMA What Keeps the Wheeze Away Dr. Janice Bacon MPHCA Annual Conference June 2016 ASTHMA Objectives Understand the effects of Asthma on the Pediatric population Understand the effects of Asthma on the
More informationLecture Notes. Chapter 3: Asthma
Lecture Notes Chapter 3: Asthma Objectives Define asthma and status asthmaticus List the potential causes of asthma attacks Describe the effect of asthma attacks on lung function List the clinical features
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP230 Section: Medical Benefit Policy Subject: Outpatient Pulmonary Rehabilitation I. Policy: Outpatient Pulmonary Rehabilitation II. Purpose/Objective: To provide
More informationMEDICAL POLICY. Proprietary Information of YourCare Health Plan
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationClinical Policy Title: Breast cancer index genetic testing
Clinical Policy Title: Breast cancer index genetic testing Clinical Policy Number: 02.01.22 Effective Date: January 1, 2017 Initial Review Date: October 19, 2016 Most Recent Review Date: October 19, 2016
More informationGINA. At-A-Glance Asthma Management Reference. for adults, adolescents and children 6 11 years. Updated 2017
GINA At-A-Glance Asthma Management Reference for adults, adolescents and children 6 11 years Updated 2017 This resource should be used in conjunction with the Global Strategy for Asthma Management and
More informationMichael S. Blaiss, MD
Michael S. Blaiss, MD Clinical Professor of Pediatrics and Medicine Division of Clinical Immunology and Allergy University of Tennessee Health Science Center Memphis, Tennessee Speaker s Bureau: AstraZeneca,
More informationASTHMA CARE FOR CHILDREN BASKET OF CARE SUBCOMMITTEE Report to: Minnesota Department of Health. June 22, 2009
This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp ASTHMA CARE FOR CHILDREN
More informationClinical Policy Title: Ear tubes (tympanostomy)
Clinical Policy Title: Ear tubes (tympanostomy) Clinical Policy Number: 1135 Effective Date: January 1, 2015 Initial Review Date: September 17, 2014 Most Recent Review Date: August 1, 2018 Next Review
More informationThe Asthma Guidelines: Diagnosis and Assessment of Asthma
The Asthma Guidelines: Diagnosis and Assessment of Asthma Christopher H. Fanta, M.D. Partners Asthma Center Brigham and Women s Hospital Harvard Medical School Objectives Know how the diagnosis of asthma
More informationCommon Diagnosis Codes and Tips for Coding Nicotine Use/
ICD-10 Tobacco Billing Guide ICD-10 and Tobacco Common Diagnosis Codes and Tips for Coding Nicotine Use/ Dependence Tobacco use is the leading cause of preventable disease and death in the United States,
More informationOn completion of this chapter you should be able to: discuss the stepwise approach to the pharmacological management of asthma in children
7 Asthma Asthma is a common disease in children and its incidence has been increasing in recent years. Between 10-15% of children have been diagnosed with asthma. It is therefore a condition that pharmacists
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Interleukin (IL)-5 Antagonists: Mepolizumab and Reslizumab Table of Contents Coverage Policy... 1 General Background... 3 Coding/Billing Information... 5
More informationPresented by the California Academy of Family Physicians 2013/California Academy of Family Physicians
Family Medicine and Patient-Centered Asthma Care Presented by the California Academy of Family Physicians Faculty: Hobart Lee, MD Disclosures: Jeffrey Luther, MD, Program Director, Memorial Family Medicine
More informationAsthma Description. Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways.
Asthma Asthma Description Asthma is a disease that affects the lungs defined as a chronic inflammatory disorder of the airways. Symptoms of asthma In susceptible individuals, this inflammation causes recurrent
More informationTHE PROMISE OF NEW AND NOVEL DRUGS. Pyng Lee Respiratory & Critical Care Medicine National University Hospital
THE PROMISE OF NEW AND NOVEL DRUGS Pyng Lee Respiratory & Critical Care Medicine National University Hospital Pyng_lee@nuhs.edu.sg Asthma Prevalence, Morbidity, Mortality 235 million suffer from asthma
More informationMEDICAL POLICY I. POLICY. POLICY TITLE POLICY NUMBER OMALIZUMAB (XOLAIR ) MP-2.123
Original Issue Date (Created): May 3, 2004 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY. Note: Initial Authorization If the patient has been maintained
More information